Safinamide Mesylate , ≥98%(HPLC) , 202825-46-5

Synonym(s):
(S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide; (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide; FCE-26743; PNU-151774E, NW-1015

CAS NO.：202825-46-5

Empirical Formula: C17H19FN2O2.CH4O3S

Molecular Weight: 398.449

MDL number: MFCD15145475

PRODUCT Properties

• Melting point: 210° (dec)
• alpha: D25 +12.9° (c = 1.1% in 98% acetic acid)
• storage temp.: 2-8°C
• solubility: H2O: ≥15mg/mL
• form: powder
• color: white to tan
• optical activity: [α]/D +9.5 to +14°, c = 1 (95% acetic acid)

Description and Uses

Safinamide methanesulfonate was approved in February 2015 by the EMA for the treatment of mid- to late-stage fluctuating Parkinson’s disease. This approval included use of the drug as an add-on therapy for use with levodopa, either alone or in combination with other existing therapies for Parkinson’s disease.51 Safinamide methanesulfonate, an oral α-aminoamide originally discovered by Farmitalia Carlo Erba and later developed by Newron/Zambon, functions as a highly selective and reversible inhibitor of MAO-B, leading to increased levels of dopamine and subsequent improvement in the motor symptoms of Parkinson’s disease, side effects that often result from use of other traditional treatments relying on dopamine replacement therapy.

Safinamide mesylate salt has been used as a reference drug to study its inhibitory effect on human monoamine oxidases (hMAO-A and hMAO-B).

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Warning
• Hazard statements: H302-H319-H361d
• Precautionary statements: P202-P264-P270-P301+P312-P305+P351+P338-P308+P313
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3